Contraindications for combined use of brigatinib

Contraindications for the combined use of brigatinib mainly include concurrent use with strong or moderate inhibitors of CYP3A, strong or moderate inducers of CYP3A, and potential interactions with other drugs.

1. Concomitant use with strong or moderate CYP3A inhibitors is contraindicated

Concurrent use of brigatinib with strong or moderateCYP3A inhibitors (such as grapefruit juice, amiodarone, erythromycin, etc.) may increase the plasma concentration of brigatinib, thereby increasing the incidence of adverse reactions. These adverse reactions may include, but are not limited to, nausea, vomiting, diarrhea, abnormal liver function, etc. Therefore, the concomitant use of brigatinib with these drugs should be avoided. If this cannot be avoided, the brigatinib dose should be reduced by approximately 50% to reduce the risk of adverse effects.

2. Contraindicated in combined use with strong or moderate CYP3A inducers

Concurrent use with strong or moderateCYP3A inducers (such as rifampicin, carbamazepine, phenytoin, etc.) may reduce the plasma concentration of brigatinib, thus affecting its efficacy. Therefore, this combined use should also be avoided. If this cannot be avoided, the efficacy of brigatinib should be closely monitored and dose adjustments made as necessary.

3. Potential interactions with other drugs

In addition to interactions withCYP3A inhibitors and inducers, brigatinib may interact with other drugs. For example, brigatinib may decrease concentrations of CYP3A substrates, including hormonal contraceptives, resulting in loss of efficacy. Therefore, you should use other drugs with caution and seek the advice of your doctor or pharmacist while using brigatinib.

References:

https://www.drugs.com/drug-interactions/brigatinib.html